Cilostazol in patients with ischemic stroke

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1305-1315

  Al Qudah, Zaid A ^a   Hassan, Ameer E ^a   Qureshi, Adnan I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

acute ischemic stroke; cilostazol; neurointerventional procedures

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CILOSTAZOL; CLOPIDOGREL; CYCLIC AMP; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROMYCIN; HYPOCHLOROUS ACID; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOTHIONEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEPRAZOLE; PADGEM PROTEIN; PENTOXIFYLLINE; PLACEBO; TICLOPIDINE;

ARTERIAL WALL THICKNESS; ARTERY OCCLUSION; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CELL ACTIVATION; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DIZZINESS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENDOTHELIUM CELL; FOLLOW UP; HEADACHE; HEART DEATH; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART PALPITATION; HUMAN; HYPEROXIA; INTERMITTENT CLAUDICATION; LIPID BLOOD LEVEL; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUTROPHIL; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK REDUCTION; STEADY STATE; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION INHIBITORS; STROKE; TETRAZOLES;

EID: 79955796312     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.576248     Document Type: Article

References (29)

1. US Department of Health and Human Services, Food and Drug Adminstration.NME drug and new biological approval in 1999.Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ NMEDrugandNewBiologicApprovals/ucm081686.htm [Last accessed 10 September 2010]
2. Shinohara Y, Katayama Y, Uchiyama S, et al.Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.Lancet Neurol 2010;9:959-68
3. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J.Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.Cardiovasc Drug Rev 2001;19:369-86 (Pubitemid 34260705)
4. Honda F, Imai H, Ishikawa M, et al.Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia.Stroke 2006;37:223-8 (Pubitemid 43732075)
5. Hankey GJ, Eikelboom JW.Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.Lancet Neurol 2010;9:273-84
6. Fumio Gotoh HT, Hirai S, Terashi A, et al.Cilostazol in stroke prevention.J Stroke Cerebrovasc Dis 2000;9:147-57
7. Nakamura T, Uchiyama S, Yamazaki M, Iwata M.Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.Thromb Res 2007;119:511-16 (Pubitemid 46149895)
8. Goto S.Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.Atheroscler Suppl 2005;6:3-11 (Pubitemid 43263084)
9. Omi H, Okayama N, Shimizu M, et al.Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production.Microvasc Res 2004;68:119-25 (Pubitemid 39093885)
10. Kitamoto S, Egashira K.Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease.J Atheroscler Thromb 2002;9:261-5
11. Cojocaru IM, Cojocaru M, Iliescu I, et al.Plasma myeloperoxidase levels in patients with acute ischemic stroke.Rom J Intern Med 2010;48:101-4
12. Hong KW, Lee JH, Kima KY, et al.Cilostazol: therapeutic potential against focal cerebral ischemic damage.Curr Pharm Des 2006;12:565-73
13. Nonaka Y, Koumura A, Hyakkoku K, et al.Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.J Pharmacol Exp Ther 2009;330:13-22
14. Suzuki S, Masui Y, Ohnuki M, et al.Induction of metallothionein synthesis by cilostazol in mice and in human cultured neuronal cell lines.Biol Pharm Bull 2007;30:791-4 (Pubitemid 46570981)
15. Hiratsuka M, Hinai Y, Sasaki T, et al.Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.Drug Metab Dispos 2007;35:1730-2 (Pubitemid 47481597)
16. Yoo HD, Park SA, Cho HY, et al.Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.Clin Pharmacol Ther 2009;86:281-4
17. Lee SP, Suh JW, Park KW, et al.Study design and rationale of Influence of cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T) study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.Trials 2010;11:87
18. CAPRIE Steering Committee.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet 1996;348:1329-39
19. Hass WK, Easton JD, Adams HP Jr., et al.Ticlopidine Aspirin Stroke Study Group.A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients.N Engl J Med 1989;321:501-7 (Pubitemid 19203874)
20. Lee JH, Cha JK, Lee SJ, et al.Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.Eur J Neurol 2010;17:434-42
21. Huang Y, Cheng Y, Wu J, et al.Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.Lancet Neurol 2008;7:494-9
22. Kwon SU, Cho YJ, Koo JS, et al.Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebocontrolled trial of cilostazol in symptomatic intracranial arterial stenosis.Stroke 2005;36:782-6
23. Samsung Medical Center.The comparison of effects between increased dose of clopidogrel and addition of cilostazol (4C-DES).Clincaltrials.gov.2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00620646? term=clopidogrel+AND +cilostazol&rank=1 [Last accessed 10 September 2010]
24. Translational Research Informatics Center, Hyogo, Japan.Cilostazol- aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS).2009.Available from: http://www.strokecenter.org/trials/TrialDetail. aspx?tid=624 [Last accessed 10 September 2010]
25. Korea Otsuka Pharmaceutical Co.Effect of cilostazol in the acute lacunar infarction based on pulsatility index of transcranial doppler (ECLIPse).2009.Available from: http://www.strokecenter.org/trials/TrialDetail. aspx?tid=738 [Last accessed 10 September 2010].
26. Yamasaki Y, Kim YS, Kawamori R.Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study).Cardiovasc Diabetol 2006;5:16
27. Han Y, Li Y, Wang S, et al.Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.Am Heart J 2009;157:733-9
28. Ge J, Han Y, Jiang H, et al.RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.J Cardiovasc Pharmacol 2005;46:162-6 (Pubitemid 41060208)
29. Takigawa T, Matsumaru Y, Hayakawa M, et al.Cilostazol reduces restenosis after carotid artery stenting.J Vasc Surg 2010;51:51-6